• News

"Psoriasis Cream Succeeds in Early Trial" - Kristen Monaco

  • Medpage Today
  • New York, NY
  • (July 15, 2020)

An investigational, topical cream that inhibits phosphodiesterase type 4 (PDE-4) was effective at clearing plaque psoriasis in a double-blind, phase IIb trial.

Meeting the trial's primary endpoint, 28% of patients treated with a 0.3% concentration of roflumilast and 23% of patients on a lower dose (0.15%) had clear or almost clear skin after 6 weeks, as compared to 8% of those given a placebo cream (P<0.001 and P=0.004 vs placebo, respectively), reported Mark Lebwohl, MD, of the Icahn School of Medicine at Mount Sinai in New York City, and colleagues.

Learn more